News
16h
Barchart on MSNEli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...
A new clinical trial has revealed that tirzepatide (Zepbound) surpasses semaglutide (Wegovy) in promoting weight loss among ...
Many stars have weighed in on injectables like Ozempic, Mounjaro and Wegovy. And with the stigma shifting, Rosie O'Donnell, Meghan Trainor, Scott Disick and others are proclaiming their benefits.
Telehealth platform Hims & Hers said on Friday it will cut 68 employees, or about 4% of its workforce, as it adjusts to a U.S ...
Novo Nordisk was Europe's most valuable company, with a big lead on obesity drugs with its runaway hits Ozempic and Wegovy.
As the Food and Drug Administration clamps down on off-brand weight loss medications, Seattle-area residents are stocking up ...
Novo Nordisk (NVO) makes Ozempic, the best-known GLP-1 drug out today. And until quite recently, the Danish pharma giant ...
Explore the evolving landscape of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity, highlighting access ...
The agreement unites two brands that are popular with Gen Z and helps the buyer diversify its supply chain outside of China. Pipeline operator Williams will seek to build two natural-gas supply lines ...
Patients have reported dental issues like tooth decay and dry mouth after taking GLP-1s like Ozempic for weight loss, though ...
Salesforce delivered a beat-and-raise quarter even with President Trump’s imposition of tariffs on imported goods.
The percentage of adults prescribed a GLP-1 drug like Wegovy or Zepbound jumped almost sevenfold over the past five years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results